Evidence map›Paper›PMID 32633856›Full record

SynthesisThe Cochrane database of systematic reviews2020

Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease.

Thomas Struyf, Jonathan J Deeks, Jacqueline Dinnes, Yemisi Takwoingi, Clare Davenport, Mariska Mg Leeflang, René Spijker, Lotty Hooft, Devy Emperador, Sabine Dittrich and 4 more

Open access · bronzeAbstract readSystematic Review
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 263 papers, 25 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
263citing papers in PubMed, 25 pooled it
51.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

263 citing papers in PubMed, 25 syntheses or guidelines pooled it, 614 citations in OpenAlex.

  1. SPECT/CT Scan Images to Evaluate COVID-19 Pulmonary Complications: A Systematic Review.International journal of environmental research and public health · 2025
    Pooled it
  2. Pooled it
  3. Antiplatelet agents for the treatment of adults with COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Fluvoxamine for the treatment of COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  8. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  9. Janus kinase inhibitors for the treatment of COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  10. Pooled it
  11. Thoracic imaging tests for the diagnosis of COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  12. Inhaled corticosteroids for the treatment of COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  13. Pooled it
  14. Guideline
  15. Pooled it
  16. Antibiotics for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  17. Colchicine for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  18. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  19. Guideline
  20. Interventions for palliative symptom control in COVID-19 patients.The Cochrane database of systematic reviews · 2021
    Pooled it

203 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 4 countries.

Thomas StruyfDepartment of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Jonathan J DeeksTest Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Jacqueline DinnesTest Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Yemisi TakwoingiTest Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Clare DavenportTest Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Mariska Mg LeeflangDepartment of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
René SpijkerMedical Library, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Amsterdam, Netherlands.
Lotty HooftCochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Devy EmperadorFIND, Geneva, Switzerland.
Sabine DittrichFIND, Geneva, Switzerland.
Julie DomenDe Wijkpraktijk, Antwerp, Belgium.
Sebastiaan R A HornDe Wijkpraktijk, Antwerp, Belgium.
Ann Van den BruelDepartment of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Cochrane COVID-19 Diagnostic Test Accuracy GroupNIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.
University Hospitals Birmingham NHS Foundation Trust · GBFoundation for Innovative New Diagnostics · CHKU Leuven · BEAmsterdam University Medical Centers · NLUniversity Medical Center Utrecht · NLUniversity of Birmingham · GBUtrecht University · NL

Funding

Department of Health CS-2015-15-016
6 · The paper itself

Abstract

backgroundSome people with SARS-CoV-2 infection remain asymptomatic, whilst in others the infection can cause mild to moderate COVID-19 disease and COVID-19 pneumonia, leading some patients to require intensive care support and, in some cases, to death, especially in older adults. Symptoms such as fever or cough, and signs such as oxygen saturation or lung auscultation findings, are the first and most readily available diagnostic information. Such information could be used to either rule out COVID-19 disease, or select patients for further diagnostic testing.

objectivesTo assess the diagnostic accuracy of signs and symptoms to determine if a person presenting in primary care or to hospital outpatient settings, such as the emergency department or dedicated COVID-19 clinics, has COVID-19 disease or COVID-19 pneumonia. SEARCH

methodsOn 27 April 2020, we undertook electronic searches in the Cochrane COVID-19 Study Register and the University of Bern living search database, which is updated daily with published articles from PubMed and Embase and with preprints from medRxiv and bioRxiv. In addition, we checked repositories of COVID-19 publications. We did not apply any language restrictions. SELECTION CRITERIA: Studies were eligible if they included patients with suspected COVID-19 disease, or if they recruited known cases with COVID-19 disease and controls without COVID-19. Studies were eligible when they recruited patients presenting to primary care or hospital outpatient settings. Studies including patients who contracted SARS-CoV-2 infection while admitted to hospital were not eligible. The minimum eligible sample size of studies was 10 participants. All signs and symptoms were eligible for this review, including individual signs and symptoms or combinations. We accepted a range of reference standards including reverse transcription polymerase chain reaction (RT-PCR), clinical expertise, imaging, serology tests and World Health Organization (WHO) or other definitions of COVID-19. DATA COLLECTION AND ANALYSIS: Pairs of review authors independently selected all studies, at both title and abstract stage and full-text stage. They resolved any disagreements by discussion with a third review author. Two review authors independently extracted data and resolved disagreements by discussion with a third review author. Two review authors independently assessed risk of bias using the QUADAS-2 checklist. Analyses were descriptive, presenting sensitivity and specificity in paired forest plots, in ROC (receiver operating characteristic) space and in dumbbell plots. We did not attempt meta-analysis due to the small number of studies, heterogeneity across studies and the high risk of bias. MAIN

resultsWe identified 16 studies including 7706 participants in total. Prevalence of COVID-19 disease varied from 5% to 38% with a median of 17%. There were no studies from primary care settings, although we did find seven studies in outpatient clinics (2172 participants), and four studies in the emergency department (1401 participants). We found data on 27 signs and symptoms, which fall into four different categories: systemic, respiratory, gastrointestinal and cardiovascular. No studies assessed combinations of different signs and symptoms and results were highly variable across studies. Most had very low sensitivity and high specificity; only six symptoms had a sensitivity of at least 50% in at least one study: cough, sore throat, fever, myalgia or arthralgia, fatigue, and headache. Of these, fever, myalgia or arthralgia, fatigue, and headache could be considered red flags (defined as having a positive likelihood ratio of at least 5) for COVID-19 as their specificity was above 90%, meaning that they substantially increase the likelihood of COVID-19 disease when present. Seven studies carried a high risk of bias for selection of participants because inclusion in the studies depended on the applicable testing and referral protocols, which included many of the signs and symptoms under study in this review. Five studies only included participants with pneumonia on imaging, suggesting that this is a highly selected population. In an additional four studies, we were unable to assess the risk for selection bias. These factors make it very difficult to determine the diagnostic properties of these signs and symptoms from the included studies. We also had concerns about the applicability of these results, since most studies included participants who were already admitted to hospital or presenting to hospital settings. This makes these findings less applicable to people presenting to primary care, who may have less severe illness and a lower prevalence of COVID-19 disease. None of the studies included any data on children, and only one focused specifically on older adults. We hope that future updates of this review will be able to provide more information about the diagnostic properties of signs and symptoms in different settings and age groups. AUTHORS'

conclusionsThe individual signs and symptoms included in this review appear to have very poor diagnostic properties, although this should be interpreted in the context of selection bias and heterogeneity between studies. Based on currently available data, neither absence nor presence of signs or symptoms are accurate enough to rule in or rule out disease. Prospective studies in an unselected population presenting to primary care or hospital outpatient settings, examining combinations of signs and symptoms to evaluate the syndromic presentation of COVID-19 disease, are urgently needed. Results from such studies could inform subsequent management decisions such as self-isolation or selecting patients for further diagnostic testing. We also need data on potentially more specific symptoms such as loss of sense of smell. Studies in older adults are especially important.

Indexed as

Ambulatory CareBetacoronavirusPrimary Health CareSymptom AssessmentArthralgiaCoronavirus InfectionsCOVID-19FatigueFeverHeadacheHumansMyalgiaOutpatient Clinics, HospitalPandemicsPhysical ExaminationPneumonia, Viral

Identifiers

PMID32633856
PMCPMC7386785
OpenAlexW3038174280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.